Literature DB >> 2959289

Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus.

F Moldenhauer1, J David, A H Fielder, P J Lachmann, M J Walport.   

Abstract

There is a deficiency of complement receptor type 1 (CR1) on the erythrocytes of patients with systemic lupus erythematosus (SLE). This receptor is involved in the processing of immune complexes. Whether the deficiency is inherited or acquired has been the subject of controversy. A restriction fragment length polymorphism (RFLP), identified using a complementary DNA probe for CR1, has been correlated with the numeric expression of CR1 on normal erythrocytes. The gene frequency for the 2 alleles defined by this RFLP was compared in 44 patients with SLE (from 42 families), 43 of their consanguineous relatives, and 50 nonrelated normal subjects. The gene frequency for the alleles correlating with high and low expression of CR1 was 0.73 and 0.27, respectively, in the normal subjects. The gene frequency was not significantly different in the SLE patients. However, the SLE patients expressed fewer CR1 molecules per erythrocyte within each genotype, compared with normal subjects and compared with their consanguineous relatives. The low allele for numeric expression of CR1 on erythrocytes is not a disease susceptibility gene for SLE.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959289     DOI: 10.1002/art.1780300901

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

1.  CR1 polymorphism in hydralazine-induced systemic lupus erythematosus: DNA restriction fragment length polymorphism.

Authors:  J A Mitchell; R B Sim; E Sim
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

2.  Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis.

Authors:  Swapan K Nath; John B Harley; Young Ho Lee
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

Review 3.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

6.  C3b receptor (CR1) genomic polymorphism in rheumatoid arthritis. Low receptor levels on erythrocytes are an acquired phenomenon.

Authors:  A Kumar; A N Malaviya; S Sinha; P S Khandekar; K Banerjee; L M Srivastava
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

7.  Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study.

Authors:  K Hartung; M P Baur; R Coldewey; M Fricke; J R Kalden; H J Lakomek; H H Peter; D Schendel; P M Schneider; S A Seuchter
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Does reduced erythrocyte C3b receptor (CR1) activity contribute to the pathogenesis of yersinia triggered reactive arthritis?

Authors:  R Lahesmaa; E Eerola; A Toivanen
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  An anti-peptide antibody that recognizes a neo-antigen in the CR1 stump remaining on erythrocytes after proteolysis.

Authors:  J E Barbosa; R A Harrison; P J Barker; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

10.  A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria.

Authors:  Ian A Cockburn; Margaret J Mackinnon; Angela O'Donnell; Stephen J Allen; Joann M Moulds; Moses Baisor; Moses Bockarie; John C Reeder; J Alexandra Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.